Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2017 ASCO Annual Meeting /
Olaparib slows growth of BRCA-related metastatic breast cancer

2nd - 6th Jun 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.17
Views: 1155

Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Robson presents, at a press conference at ASCO 2017, findings from a phase III clinical trial of around 300 women that may introduce PARP inhibitors as a new type of treatment for breast cancer.

Read the news story for more.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation